- $2.34bn
- $1.08bn
- $548.51m
Vesting of awards under Long Term Incentive Plan
Brief: Hutchmed (China) Says Ipsen Initiates Market Withdrawal And Recall Of Tazverik In China
Brief: HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Update on Licensed Oncology Product in China
Directorate change
Publication of Form 20-F
Brief: HUTCHMED (China) Logs FY Net Income Attributable $456.9 Mln
2025 Full Year Results and Business Updates
HUTCHMED Initiates Global Trial of ATTC Candidate
HUTCHMED to Announce 2025 Final Results
Publication of Phase III Results in The Lancet
Positive Topline Results of Phase III Trial
Brief: Hutchmed Announces Positive Topline Phase III Trial Of Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia
Surufatinib + Camrelizumab PDAC Phase 3 initiation
Brief: Hutchmed (China) Says NDA For Savolitinib Accepted With Priority Review In China
China NDA Acceptance-Savolitinib in Gastric Cancer
Brief: Hutchmed (China) Says NDA For Fanregratinib Accepted With Priority Review In China
NDA Acceptance in China for Fanregratinib
HUTCHMED Initiates Development of ATTC Candidate